We identified compounds that could selectively inhibit BAP1 deubiquitinase activity using an enzymatic activity assay approach, then demonstrated preclinical antitumor efficacy of BAP1 inhibition using these compounds in cell line and xenograft models of myeloma with ASXL1 frameshift mutations (20). Here, BAP1 is linked to plasma cell myeloma.